Market Trends of Benign Prostatic Hyperplasia (BPH) Treatment Devices Industry
The Laser-based Devices Segment is Expected to Witness Significant Growth Over the Forecast Period
Laser-based devices refer to medical technologies that use laser energy treatments that are less invasive than traditional surgical methods like transurethral resection of the prostate (TURP). These devices are designed to precisely remove or vaporize excess prostate tissue that is causing urinary obstruction and related symptoms, such as difficulty urinating, frequent urination, and weak urine flow.
The laser-based devices segment is gaining momentum due to the effectiveness and safety of the devices in treating lower urinary tract symptoms (LUTS) associated with BPH. For instance, according to a study published in the Journal of Urology in January 2024, photoselective vaporization of the prostate (PVP) utilizing laser technology was a preferred treatment option, especially for patients with specific medical considerations. The use of 120 W or 180 W laser platforms is effective; studies have demonstrated that these platforms offer comparable efficacy to other treatments, such as transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) in prostates ranging from 80 to 150 g.
Therefore, the segment is experiencing growth due to the combination of efficacy, safety, and suitability of the devices for medically complicated patients.
The advanced laser system is designed to offer precise, minimally invasive treatment for BPH, making it a preferred choice for both patients and healthcare providers. For instance, in April 2023, Olympus Corporations' SOLTIVE SuperPulsed Thulium Fiber Laser, known for its efficacy in vaporizing prostate tissue with minimal thermal damage, represented a significant advancement in BPH care and was presented during the American Urology Association (AUA) annual meeting in Chicago.
Hence, there is an increasing demand for highly effective and minimally invasive alternatives to traditional surgical methods, which is expected to drive the segment’s growth.
North America is Expected to Dominate the Market
North America's leading position in the market is mostly due to the higher prevalence of BPH. The increase in innovations in minimally invasive treatments and rising advancements in treatment approaches drive the market's growth in the region.
The benign prostatic hyperplasia (BPH) treatment devices market in North America is significantly influenced by the growing adoption of novel surgical treatments (NSTs). For instance, a study published in European Urology Focus in April 2024 showed that a retrospective observational analysis of BPH surgical procedures from 2011 to 2022 revealed a notable increase in the utilization of NSTs in the United States and highlighted the mean reimbursement for NSTs at 1.43 times higher than for traditional procedures. Therefore, the increasing preference for these advanced treatment options reflects the broader trend toward personalized, minimally invasive interventions in BPH management in the United States, contributing to sustained market growth and innovation.
The BPH treatment devices market in Canada is set for continued growth due to innovations in minimally invasive treatments supported by institutional research, which improve patient outcomes. For instance, in September 2023, research institutions, like the University Health Network in Toronto, highlighted that approximately 50% of men over 50 experienced symptoms of BPH. The university’s contributions to clinical research and technological development play a crucial role in shaping the market and improving patient outcomes.
Additionally, the technological advancements and approvals contribute to expansion in the BPH treatment devices market as more patients and healthcare providers seek less invasive and more effective treatment options. For instance, in June 2023, Urotronic, Inc. got Food and Drug Administration approval for the Optilume BPH Catheter System in the United States, designed to enhance urinary flow by treating the urethral blockage caused by BPH. The system utilizes a unique combination of pre-dilation and drug-coated balloon catheters. As the demand for such innovative devices continues to grow, the market is expected to witness sustained growth in the region.
Established key players in this region focus on technological advancements and the adoption of novel surgical treatments. Owing to these factors, the region is the leader in the market.
